SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Stanton, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanton, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Potential of renin inhibition in cardiovascular disease

Alice Stanton

Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, St Stephen's Green, Dublin 2, Ireland, astanton{at}rcsi.ie

Since renin catalyses the first and rate-limiting step of the renin-angiotensin system (RAS) cascade, interruption of the generation of angiotensin II (Ang II) by renin inhibitors at this highly specific initial step of the cascade has long been a therapeutic goal. The early development of renin inhibitors was hampered by problems with bioavailability and high costs of synthesis. However, more recently a potent non-peptidic inhibitor of renin, aliskiren, with acceptable oral bioavailability, has been synthesised. Aliskiren effectively reduces Ang II levels in normal volunteers and has been shown to lower blood pressure (BP) in patients with mild-to-moderate hypertension.

Renin inhibitors would be expected to have similar, but not identical effects to those of the established RAS antagonists. Due to the lack of effective alternative enzyme pathways, blockade of Ang II production may be more effective with renin inhibition than with angiotensin-converting enzyme (ACE) inhibition.

Furthermore, because renin has high specificity for only one substrate, angiotensinogen, side-effects would be expected to be less frequent. It is currently unclear whether blockade of Ang II type 1 (AT1) receptors, leaving other Ang II receptors (AT2, AT3 and AT4) unblocked, is preferable to the reduction in plasma and tissue Ang II levels achieved with either ACE or renin inhibition.

Pharmacological suppression of the RAS, through ACE inhibition, or blockade of AT1, β-adrenoceptor or mineralocorticoid receptors, has been proven to reduce morbidity and mortality in patients with hypertension, diabetes mellitus, atherosclerosis, heart failure and nephropathy. While, to date, aliskiren has only been shown to reduce BP, it appears likely that orally-active renin inhibitors could prove useful in the management of a wide range of cardiovascular pathologies.

Key Words: renin • renin inhibition • renin angiotensin system • blood pressure • vascular disease • atherosclerosis

References

  • Oparil S., Haber E. The renin-angiotensin system. N Engl J Med 1974;291:381-401/446-57.[Web of Science][Medline] [Order article via Infotrieve]
  • Dzau VJ Tissue angiotensin and pathobiology of vascular disease, a unifying hypothesis. Hypertension 2001;37:1047-52.[Abstract/Free Full Text]
  • Tigerstedt R., Bergman PG Niere und Kreislauf. SkandArc Physiol 1898;8:223-71.
  • Braun-Menedez E., Fasciolo JC, Leloir LF, Munoz JM La substancia hipertenora de la sangre del rinon isquemiado. Rev Soc Arg Biol 1939;15:420-30.
  • Page IH, Helmer OM A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin activator. J Exp Med 1940;71:29-42.[Abstract]
  • Brunner HR, Laragh JH, Baer L. et al. Essential hypertension: Renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Burton J., Cody RJ, Herd JA, Haber E. Specific inhibition of renin by an angiotensinogen analog: studies in sodium depletion and renin-dependent hypertension. Proc Natl Acad Sci 1980;77:5476-9.[Abstract/Free Full Text]
  • Dzau VJ, Kopelman RI, Barger AC, Nussberger J., Haber E. Comparison of reni-specific IgG and antibody fragment in studies of blood pressure regulation. Am J Physiol 1984;246: H404-09.[Web of Science][Medline] [Order article via Infotrieve]
  • Weber MA, Neutel JM, Essinger I., Glassman HM, Boger RS, Luther RR Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Circulation 1990;81:1768-74.[Abstract/Free Full Text]
  • Neutel JM, Luther RR, Boger RS, Weber MA Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat. Am Heart J 1991;122:1094-100.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • van den Meiracker AH, Admiraal PJJ, Derkx FHM et al. Comparison of blood pressure and angiotensin responses to the renin inhibitor RO 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension. J Hypertens 1993;11:831-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kobrin I., Viskoper RJ, Laszt A., Bok J., Weber C., Charlon V. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am J Hypertens 1993;6: 349-58.[Web of Science][Medline] [Order article via Infotrieve]
  • Hollenberg NK, Fisher NDL, Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme the last word? Hypertension 1995;26:602-09.[Abstract/Free Full Text]
  • Fisher ND, Hollenberg NK Is there a future for renin inhibitors? Exp Op Invest Drugs 2001;10:417-26.[CrossRef]
  • Oefner C., Binggeli A., Breu V. et al. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases. Chem Biol 1999;6:127-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rahuel J., Rasetti V., Maibaum J. et al. Structure-based drug design: the discovery of novel non peptide orally active inhibitors of human renin. Chem Biol 2000;7:493-504.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nussberger J., Wuerzner G., Jensen C., Brunner HR Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension 2002;39:e1-e8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stanton AV, Jensen C., Mann J., O'Brien ET BP lowering with SPP 100: a novel orally active renin inhibitor - a pilot study. Hypertension 2001;38:526, P202. (abstract).
  • StantonA., Barton J., Jensen C., BobillierA., Mann J., O'Brien E. Dose response antihypertensive efficacy of aliskiren (SPP 100), an orally active renin inhibitor. Am J Hypertens 2002;15(Part 2 of 2):56A.
  • Barlucchi L., Leri A., Dostal DE et al. Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res 2001;88:298-304.[Abstract/Free Full Text]
  • Re RN The nature of intracrine peptide hormone action. Hypertension 1999;34:534-8.[Abstract/Free Full Text]
  • Wolny A., Clozel JP, Rein J. et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997;80:219-27.[Abstract/Free Full Text]
  • El-Amrani A-IK, Menard J., Gonzales MF, Michel JB Effects of blocking the angiotensin II receptor, converting enzyme and renin activity on the renal haemodynamics of normotensive guinea pigs. J Cardiovasc Pharmacol 1993;22:231-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Hollenberg NK, Fisher NDL. Renal circulation and blockade of the renin-angiotensin system. Hypertension 1995;26: 602-09.[Abstract/Free Full Text]
  • Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993;43:1-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fisher NDL,Allan D., Kifor I. et al. Responses to converting enzyme and renin inhibition: role of angiotensin II in humans. Hypertension 1994;23:44-51.[Abstract/Free Full Text]
  • Sunman W., Sever PS Non-angiotensin effects of angiotensin-converting enzyme inhibitors. Clin Sci 1993;85: 661-70.[Web of Science][Medline] [Order article via Infotrieve]
  • Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12.[Free Full Text]
  • Swanson GN, Harding JW Discovery of a distinct binding site for angio (3-8), a putative AT4 receptor. Regul Pept 1993; 40:409-19.[CrossRef][Web of Science]
  • Kerins DM, Hao Q., Vaughan DE Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide Angiotensin IV. J Clin Invest 1995;96:2515-20.[Web of Science][Medline] [Order article via Infotrieve]
  • Yusef S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.[Abstract/Free Full Text]
  • PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dickstein K., Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360(9335):752-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002;89(2A):18A-25A.[Web of Science][Medline] [Order article via Infotrieve]
  • DelliPizzi AM, Hilchey SD, Bell-Quilley CP Natriuretic action of angio (1-7). Brit J Pharmacol 1994;111:1-3.[Web of Science][Medline] [Order article via Infotrieve]
  • Li P., Chappell MC, Ferrario CM et al. Angiotensin (1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide.Hypertension 1997;29:394-400.[Abstract/Free Full Text]
  • Freeman EJ, Chisolm GM, Ferrario CM et al.Angiotensin-(1-7) inhibits vascular smooth muscle growth. Hypertension 1996;28:104-08.[Abstract/Free Full Text]
  • Loot AE, Roks AJM, Henning RH et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002;105:1548-50.[Abstract/Free Full Text]
  • Mahon JM, Carr RD, Nicol AK, Henderson IW Angiotensin (1-7) is an antagonist at the type 1 angiotensin II receptor. J Hypertens 1994;12:1377-81.[Web of Science][Medline] [Order article via Infotrieve]
  • Brosnihan KB, Li P., Ferrario CM Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996;27:523-8.[Abstract/Free Full Text]
  • Chappell MC, Pirro NT, Sykes A., Ferrario CM Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 1998;31(1 pt 2): 362-7.[Abstract/Free Full Text]
  • Luque M., Martin P., Martell N. et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996;14:799-805.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Iyer SN, Chappell MC, Averill DB et al. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998;31:699-705.[Abstract/Free Full Text]
  • Yusuf S., Reddy S., Ôunpuu S.,Anand S. Global burden of cardiovascular diseases. Circulation 2001;104:2746-53.[Abstract/Free Full Text]
  • Beta Blocker Heart Attack Trial Research Group. A randomised trial of propranolol in patients with acute myocardial infarction: mortality results.JAMA 1982;247:1707.[Abstract/Free Full Text]
  • Campbell DJ, Aggarwal A., Esler M., Kaye D. Beta-blockers, angiotensin II, andACE inhibitors in patients with heart failure. Lancet 2001;358(9293):1609-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Solvd Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.[Abstract]
  • Cohn JN,Tognoni G. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.[Abstract/Free Full Text]
  • Pitt B., Zannad F., Remme WJ et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.[Abstract/Free Full Text]
  • Giatras I., Lau J., Levey AS Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomised trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997;127:337-45.[Abstract/Free Full Text]
  • Bjorck S. Mulec H., Johnsen SA, Nyberg G. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. BMJ 1990;300:904-07.[Web of Science][Medline] [Order article via Infotrieve]
  • Bjorck S. Mulec H., Johnsen SA, Norden G. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339-43.[Web of Science][Medline] [Order article via Infotrieve]
  • Brenner BM, Cooper ME, de Zeeuw D. et al.The RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
  • Lewis EJ, Hunsicker LG, Clarke WR et al.The Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
  • Dahlof B., Devereux RB, Kjeldsen SE et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 4, No. 1, 6-10 (2003)
DOI: 10.3317/jraas.2003.008
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 HypertensionHome page
E. O'Brien, J. Barton, J. Nussberger, D. Mulcahy, C. Jensen, P. Dicker, and A. Stanton
Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor Blocker
Hypertension, February 1, 2007; 49(2): 276 - 284.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. H. Gradman, R. E. Schmieder, R. L. Lins, J. Nussberger, Y. Chiang, and M. P. Bedigian
Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients
Circulation, March 1, 2005; 111(8): 1012 - 1018.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Stanton, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanton, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement